RecruitingExcessive SleepinessShift-work Disorder

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Eligible age

18–65 yrs

Accepts

All genders

Locations

21 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).

Sponsor: Axsome Therapeutics, Inc.

You may qualify if…

✓ Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD)
✓ Provides written informed consent to participate in the study before the conduct of any study procedures.
✓ Male or female, aged 18 to 65 inclusive.

You may not qualify if…

✕ Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
✕ Unable to comply with study procedures.
✕ Medically inappropriate for study participation in the opinion of the investigator.